Author： Velasco Roser Bruna Jordi
Publisher： MDPI
E-ISSN： 2305-6304|3|2|152-169
ISSN： 2305-6304
Source： Toxics, Vol.3, Iss.2, 2015-04, pp. : 152-169
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Taxane-derived agents are chemotherapy drugs widely employed in cancer treatment. Among them, paclitaxel and docetaxel are most commonly administered, but newer formulations are being investigated. Taxane antineoplastic activity is mainly based on the ability of the drugs to promote microtubule assembly, leading to mitotic arrest and apoptosis in cancer cells. Peripheral neurotoxicity is the major non-hematological adverse effect of taxane, often manifested as painful neuropathy experienced during treatment, and it is sometimes irreversible. Unfortunately, taxane-induced neurotoxicity is an uncertainty prior to the initiation of treatment. The present review aims to dissect current knowledge on real incidence, underlying pathophysiology, clinical features and predisposing factors related with the development of taxane-induced neuropathy.
Related content
Updates on Oxaliplatin-Induced Peripheral Neurotoxicity (OXAIPN)
Toxics, Vol. 3, Iss. 2, 2015-05 ,pp. :
Access to resources
Recommend
By Lee Jinyoung Freeman Jennifer L.
Toxics, Vol. 2, Iss. 3, 2014-09 ,pp. :
By Harry G. Jean Hooth Michelle J. Vallant Molly Behl Mamta Travlos Gregory S. Howard James L. Price Catherine J. McBride Sandra Mervis Ron Mouton Peter R.
Toxics, Vol. 2, Iss. 3, 2014-09 ,pp. :